Effect of GnRH analogue on the bone mineral density of precocious or early pubertal girls.
10.3345/kjp.2009.52.12.1370
- Author:
Jeong Sook LIM
1
;
Heon Seok HAN
Author Information
1. Department of Pediatrics, Chungbuk National University, College of Medicine, Cheongju, Korea. hshan@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Precocious puberty;
Bone density;
Gonadotropin releasing hormone;
Human growth hormone
- MeSH:
Bone Density;
Gonadotropin-Releasing Hormone;
Human Growth Hormone;
Puberty;
Puberty, Precocious;
Reference Values
- From:Korean Journal of Pediatrics
2009;52(12):1370-1376
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Treatment of precocity with gonadotropin releasing hormone analogue (GnRHa) might theoretically exert a detrimental effect on the bone mass during pubertal development. We investigated the short-term changes in bone mineral density (BMD) during GnRHa treatment and the enhancement in the changes with the co-administration of GnRHa and human growth hormone (hGH). METHODS: Forty girls with precocious or early puberty who were using GnRHa for more than 1 year were enrolled. Of them, 14 concurrently received hGH. Lumbar bone mineral density was measured before and after the treatment, and bone mineral density-standard deviation scores (BMD-SDSs) were compared according to chronologic age (CA) and bone age (BA), as well as according to the administration of GnRHa alone (Group I) or the co-administration of hGH and GnRHa (Group II). RESULTS: BMDs before and after treatment were in the normal range according to CA but were significantly lower according to BA (P<0.05). During treatment, BMD-SDSs did not change according to CA but significantly increased according to BA (P<0.05). BMD-SDSs in group I did not change during treatment according to CA or BA, while those in group II increased significantly according to BA (P<0.05), but not according to CA. CONCLUSION: Lumbar BMD was adequate according to CA at initial manifestation of precocity but was lower if compared to BA, that is, BMD did not increase with BA. Because co-treatment with hGH significantly increased BMD-SDSs according to BA, hGH co-treatment could be considered during GnRHa therapy.
